In a recent Business Week article Lilly’s CEO Lechleiter outlined his strategy to deal with business challenges his company is facing: “Lilly stands to lose $10 billion in annual revenues between now and the end of 2016—almost half its 2009 sales—as patents on three key drugs expire. To replace that, the company must pick up the pace of drug development.” Lilly is not alone. Almost any major pharmaceutical company faces similiar issues. In order to speed up their drug development process, Lilly uses Critical Chain as their sole operating platform to manage drug development projects. Here you find the entire article.